Exubera in 2006?
Pfizer and Sanofi-Aventis will have to wait a little longer to launch inhaled insulin (Exubera). FDA is taking a three month extension to the review, meaning a decision should come before the end of January.
Pfizer and Sanofi-Aventis will have to wait a little longer to launch inhaled insulin (Exubera). FDA is taking a three month extension to the review, meaning a decision should come before the end of January.